{"id":90396,"date":"2023-11-29T13:39:47","date_gmt":"2023-11-29T08:09:47","guid":{"rendered":"http:\/\/finservwealth.com\/aurobindo-pharma-gets-usfda-nod-for-hiv-drug\/"},"modified":"2023-11-29T13:39:47","modified_gmt":"2023-11-29T08:09:47","slug":"aurobindo-pharma-gets-usfda-nod-for-hiv-drug","status":"publish","type":"post","link":"https:\/\/finservwealth.com\/hi\/aurobindo-pharma-gets-usfda-nod-for-hiv-drug\/","title":{"rendered":"Aurobindo Pharma gets USFDA nod for HIV drug"},"content":{"rendered":"<p> The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Darunavir tablets in strengths of 600 mg and 800 mg, the Hyderabad-based drug maker said in a regulatory filing.<\/p><div id=\"finse-2570448746\" class=\"finse-content finse-entity-placement\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-9118214110898834\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-9118214110898834\" \ndata-ad-slot=\"\" \ndata-ad-format=\"auto\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/business\/aurobindo-pharma-gets-usfda-nod-for-hiv-drug_17354221.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Darunavir tablets in strengths of 600 mg and 800 mg, the Hyderabad-based drug maker said in a regulatory filing. The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Darunavir tablets in strengths of 600 mg and 800 mg, the Hyderabad-based drug maker said in a regulatory filing.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/business\/aurobindo-pharma-gets-usfda-nod-for-hiv-drug_17354221.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p> The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Darunavir tablets in strengths of 600 mg and 800 mg, the Hyderabad-based drug maker said in a regulatory filing.<\/p>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/business\/aurobindo-pharma-gets-usfda-nod-for-hiv-drug_17354221.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Darunavir tablets in strengths of 600 mg and 800 mg, the Hyderabad-based drug maker said in a regulatory filing. The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Darunavir tablets in strengths of 600 mg and 800 mg, the Hyderabad-based drug maker said in a regulatory filing.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/business\/aurobindo-pharma-gets-usfda-nod-for-hiv-drug_17354221.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>\n<p><!-- \/wp:html --> The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Darunavir tablets in strengths of 600 mg and 800 mg, the Hyderabad-based drug maker said in a regulatory filing.<\/p>","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[70],"tags":[],"class_list":["post-90396","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest-news"],"jetpack_featured_media_url":"https:\/\/www.moneycontrol.com\/news_image_files\/2023\/200x200\/p\/pharma_tablet_injection_capsule_200.jpg","_links":{"self":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/90396","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/comments?post=90396"}],"version-history":[{"count":0,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/90396\/revisions"}],"wp:attachment":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/media?parent=90396"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/categories?post=90396"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/tags?post=90396"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}